Eu­ro­pean drug reg­u­la­tor votes down Bio­gen's con­tro­ver­sial Alzheimer's drug

Fol­low­ing an oral ex­pla­na­tion held at the No­vem­ber meet­ing of the EMA’s hu­man med­i­cines com­mit­tee, Bio­gen re­ceived “a neg­a­tive trend vote” on its mar­ket­ing ap­pli­ca­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER